Renovaro Inc. - Common Stock (RENB)
0.7984
+0.0449 (5.96%)
Renovaro Inc. is a biotechnology company focused on the development of innovative therapies and solutions aimed at addressing unmet medical needs
The company specializes in advanced research and development in the field of regenerative medicine, utilizing cutting-edge technologies to create treatments that promote healing and recovery for patients suffering from various conditions. Through its commitment to scientific excellence and collaboration, Renovaro seeks to transform the healthcare landscape by bringing groundbreaking therapies from the lab to the clinic, ultimately improving patient outcomes and enhancing quality of life.
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 6, 2025
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 4, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/04/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 3, 2024
![](https://investorplace.com/wp-content/uploads/2021/05/wall-street-morning.jpg)
Pre-market stock movers are worth diving into this morning as we check out all of the hottest news investors need to know about on Friday!
Via InvestorPlace · July 26, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/10/Movers.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 10, 2024
![](https://cdn.benzinga.com/files/images/story/2024/05/21/Medical-Examination-And-Healthcare-Busin.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 21, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Renovaro Biosciences just reported results for the third quarter of 2024.
Via InvestorPlace · May 16, 2024
![](https://public.newsdirect.com/437148551/7qCvHhvO.png)
Renovaro Inc. (NASDAQRENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection
Via News Direct · May 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/04/image27.jpeg?width=1200&height=800&fit=crop)
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Via Benzinga · March 4, 2024
![](https://investorplace.com/wp-content/uploads/2023/05/short-squeeze-stocks1600.png)
Hindenburg Research's short reports are legendary, and these three companies remain firmly within the activist short-seller's sights.
Via InvestorPlace · February 22, 2024
![](https://cdn.benzinga.com/files/images/story/2024/RENB_0.png?width=1200&height=800&fit=crop)
Renovaro Biosciences confronts Hindenburg's short report fallout, highlighting tech and business leaders joining the board. Despite false claims, the company asserts confidence.
Via Benzinga · February 14, 2024
![](https://cdn.benzinga.com/files/images/story/2024/02/13/image34.jpeg?width=1200&height=800&fit=crop)
Shares of IPG Photonics Corporation (NASDAQIPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via Benzinga · February 13, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 13, 2024
![](https://cdn.benzinga.com/files/images/story/2024/RENB.png?width=1200&height=800&fit=crop)
Renovaro Biosciences navigates challenges – from a controversial merger with GEDi Cube to allegations of securities law violations.
Via Benzinga · February 13, 2024
![](https://cdn.benzinga.com/files/images/story/2023/10/20/image21.jpg?width=1200&height=800&fit=crop)
Gainers XORTX Therapeutics Inc. (NASDAQXRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday.
Via Benzinga · October 20, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 20, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/04/image14.jpg?width=1200&height=800&fit=crop)
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via Benzinga · October 4, 2023